Total Valuation
Kura Oncology has a market cap or net worth of €906.88M. The enterprise value is €480.17.
Market Cap€906.88M
Enterprise Value€480.17
Share Statistics
Kura Oncology has 88,960,620 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding88,960,620
Owned by Insiders2.58%
Owned by Institutions40.99%
Financial Efficiency
Kura Oncology’s return on equity (ROE) is -1.60 and return on invested capital (ROIC) is -48.76%.
Return on Equity (ROE)-1.60
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-48.76%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee259.55K
Profits Per Employee-1.07M
Employee Count260
Asset Turnover0.09
Inventory Turnover0.14
Valuation Ratios
The current PE Ratio of Kura Oncology is ―. Kura Oncology’s PEG ratio is -0.06.
PE Ratio―
PS Ratio13.50
PB Ratio5.23
Price to Fair Value5.23
Price to FCF-12.89
Price to Operating Cash Flow-10.81
PEG Ratio-0.06
Income Statement
In the last 12 months, Kura Oncology had revenue of 67.48M and earned -278.67M in profits. Earnings per share was -3.18.
Revenue67.48M
Gross Profit67.42M
Operating Income-303.63M
Pretax Income-278.37M
Net Income-278.67M
EBITDA-275.82M
Earnings Per Share (EPS)-3.18
Cash Flow
In the last 12 months, operating cash flow was -111.76M and capital expenditures -5.67M, giving a free cash flow of -117.43M billion.
Operating Cash Flow-111.76M
Free Cash Flow-117.43M
Free Cash Flow per Share-1.32
Dividends & Yields
Kura Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.62
52-Week Price Change55.09%
50-Day Moving Average9.08
200-Day Moving Average8.25
Relative Strength Index (RSI)60.61
Average Volume (3m)26.00
Important Dates
Kura Oncology upcoming earnings date is Oct 29, 2026, After Close (Confirmed).
Last Earnings DateAug 12, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Kura Oncology as a current ratio of 6.06, with Debt / Equity ratio of 50.49%
Current Ratio6.06
Quick Ratio6.05
Debt to Market Cap0.01
Net Debt to EBITDA0.47
Interest Coverage Ratio-200.81
Taxes
In the past 12 months, Kura Oncology has paid 297.00K in taxes.
Income Tax297.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Kura Oncology EV to EBITDA ratio is -2.84, with an EV/FCF ratio of -11.07.
EV to Sales11.59
EV to EBITDA-2.84
EV to Free Cash Flow-11.07
EV to Operating Cash Flow-12.21
Balance Sheet
Kura Oncology has €519.02M in cash and marketable securities with €24.45M in debt, giving a net cash position of €494.57M billion.
Cash & Marketable Securities€519.02M
Total Debt€24.45M
Net Cash€494.57M
Net Cash Per Share€5.56
Tangible Book Value Per Share€1.99
Margins
Gross margin is 94.73%, with operating margin of -449.94%, and net profit margin of -412.95%.
Gross Margin94.73%
Operating Margin-449.94%
Pretax Margin-412.51%
Net Profit Margin-412.95%
EBITDA Margin-408.74%
EBIT Margin-410.27%
Analyst Forecast
The average price target for Kura Oncology is €24.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€24.14
Price Target Upside171.86% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-14.46%
EPS Growth Forecast-39.49%